Search results
Results from the WOW.Com Content Network
Preliminary studies on 25C-NBOMe have shown that the substance is toxic to development, heart health, and brain health in zebrafish, rats, and Artemia salina, a common organism for studying potential drug effects on humans, but more research is needed on the topic, the dosages, and if the toxicology results apply to humans. Researchers of the ...
Preliminary studies on 25C-NBOMe have shown that the substance is toxic to development, heart health, and brain health in zebrafish, rats, and Artemia salina, a common organism for studying potential drug effects on humans, but more research is needed on the topic, the dosages, and if the toxicology results apply to humans. Researchers of the ...
Preliminary studies on 25C-NBOMe have shown that the substance is toxic to development, heart health, and brain health in zebrafish, rats, and Artemia salina, a common organism for studying potential drug effects on humans, but more research is needed on the topic, the dosages, and if the toxicology results apply to humans. Researchers of the ...
25N-NBOMe (2C-N-NBOMe, NBOMe-2C-N) is a derivative of the hallucinogen 2C-N. The pharmacological properties of 25N-NBOMe have not been described in the scientific literature, but it is believed to act in a similar manner to related compounds such as 25I-NBOMe and 25C-NBOMe , which are potent agonists at the 5HT 2A receptor .
25CN-NBOH (sometimes also referred to as NBOH-2C-CN) [1] is a compound indirectly derived from the phenethylamine series of hallucinogens, which was discovered in 2014 at the University of Copenhagen. [2] It is a member of the NBOMe family of psychedelics. [3] The drug is notable in being one of the most selective agonists of the serotonin 5-HT ...
25TFM-NBOMe (also known as NBOMe-2C-TFM, 2C-TFM-NBOMe, and Cimbi-138) is a derivative of the phenethylamine hallucinogen 2C-TFM, discovered in 2004 by Ralf Heim at the Free University of Berlin. [1]
25I-NBOH acts as a potent agonist of the 5HT 2A receptor, [2] [3] with a K i of 0.061 nM at the human 5HT 2A receptor, similar to the better-known compound 25I-NBOMe, making it some twelve times the potency of 2C-I itself. Although in vitro tests show this compound acts as an agonist, animal
25E-NBOH (2C-E-NBOH, NBOH-2C-E) is a derivative of the phenethylamine derived hallucinogen 2C-E.It was first developed by Martin Hansen at the University of Copenhagen in 2010 as a brain imaging agent, [2] but has subsequently been sold as a designer drug, first being identified in Brazil in 2018 on seized blotter paper, [3] [4] [5] as well as in Slovenia [6] and France. [7]